The impact of chronic rhinosinusitis on COVID-19 risk and outcomes: A systematic review and meta-analysis

Frontiers in Immunology

Immunology

Mahmoud Ibrahim Ahmed¹  Moustafa Abouelkheir²  Abdullah Reda³  Mustafa Mohammad Alaaraj⁴  Basant Ismail Lashin⁵  Amr Ehab El-Qushayri⁶  Jaffer Shah⁷ 

[1] Critical Care Clinical Fellow in Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom;Emergency Medicine Department, Pilgrim Hospital, United Lincolnshire NHS Trust, Lincolnshire, United Kingdom;Faculty of Medicine, Al-Azhar University, Cairo, Egypt;Faculty of Medicine, Alexandria University, Alexandria, Egypt;Trust Grade Foundation Doctor, Pilgrim Hospital, General Medicine, Boston, United Kingdom;Faculty of Medicine, Banha University, Banha, Egypt;Faculty of Medicine, Minia University, Minia, Egypt;Medical Research Center, Kateb University, Kabul, Afghanistan;

关键词: chronic rhinosinusitis;    steroids;    COVID-19;    coronavirus;    prevalence;    epidemiology;   

DOI  :  10.3389/fimmu.2023.1139031

 received in 2023-01-06, accepted in 2023-03-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundThe impact of chronic rhinosinusitis (CRS) and subsequent steroid therapy on acquiring COVID-19 and severe outcomes remains controversial. Therefore, we conducted this systematic review and meta-analysis to provide cumulative evidence regarding the risk of COVID-19 and the impact of steroid therapy, length of hospital stay, mechanical ventilation, and mortality among CRC patients.MethodsWe conducted a comprehensive electronic search strategy using the relevant keywords. The outcomes and risk factors of COVID-19 in CRS patients was estimated and compared to a healthy control group when applicable.ResultsA total of seven studies were included, with an estimated prevalence of 6.5% (95% confidence interval (CI): 2.5-15.7) for COVID-19 in the CRS group. COVID-19 prevalence did not differ between CRS and controls (odds ratio (OR): 0.92; 95%CI: 0.84-1.01; p = 0.08). Moreover, using steroid/immunosuppressive therapy did not significantly increase the risk of acquiring COVID-19 in CRS patients compared to the control group (OR: 3.31; 95%CI: 0.72-15.26; p = 0.12). Length of hospital stay, mechanical ventilation, and mortality rates were comparable between the two groups. Furthermore, we found that male sex, cardiovascular morbidity, renal diseases, and hypertension were inversely associated with COVID-19 infection (p < 0.01).ConclusionCRS had a neutral effect on acquiring COVID-19 and developing severe outcomes. However, further studies are needed.

【 授权许可】

Unknown   
Copyright © 2023 Reda, Lashin, Alaaraj, Abouelkheir, Ahmed, Shah and El-Qushayri